{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T06:52:33Z","timestamp":1780987953469,"version":"3.54.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2010,11,16]],"date-time":"2010-11-16T00:00:00Z","timestamp":1289865600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Hematol Malig Rep"],"published-print":{"date-parts":[[2011,3]]},"DOI":"10.1007\/s11899-010-0067-5","type":"journal-article","created":{"date-parts":[[2010,11,15]],"date-time":"2010-11-15T06:19:23Z","timestamp":1289801963000},"page":"67-72","source":"Crossref","is-referenced-by-count":10,"title":["The Emerging Role of Histone Deacetylase Inhibitors in Treating T-cell Lymphomas"],"prefix":"10.1007","volume":"6","author":[{"given":"Steven M.","family":"Horwitz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,11,16]]},"reference":[{"key":"67_CR1","first-page":"76","volume":"92","author":"C Gisselbrecht","year":"1998","unstructured":"Gisselbrecht C, Gaulard P, Lepage E, et al.: Prognostic significance of T-cell phenotype in aggressive non-Hodgkin\u2019s lymphomas. Groupe d\u2019Etudes des Lymphomes de l\u2019Adulte (GELA). Blood 1998, 92:76\u201382.","journal-title":"Blood"},{"key":"67_CR2","doi-asserted-by":"crossref","first-page":"4357","DOI":"10.1200\/JCO.2008.20.8470","volume":"27","author":"OA O\u2019Connor","year":"2009","unstructured":"O\u2019Connor OA, Horwitz S, Hamlin P, et al.: Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies. J Clin Oncol 2009, 27:4357\u201364.","journal-title":"J Clin Oncol"},{"key":"67_CR3","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1093\/annonc\/mdn542","volume":"20","author":"A Jaccard","year":"2009","unstructured":"Jaccard A, Petit B, Girault S, et al.: L-asparaginase-based treatment of 15 western patients with extranodal NK\/T-cell lymphoma and leukemia and a review of the literature. Ann Oncol 2009, 20:110\u20136.","journal-title":"Ann Oncol"},{"key":"67_CR4","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1093\/jnci\/92.15.1210","volume":"92","author":"PA Marks","year":"2000","unstructured":"Marks PA, Richon VM, Rifkind RA. Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst 2000, 92:1210\u20136.","journal-title":"J Natl Cancer Inst"},{"key":"67_CR5","doi-asserted-by":"crossref","first-page":"3971","DOI":"10.1200\/JCO.2005.16.600","volume":"23","author":"KN Bhalla","year":"2005","unstructured":"Bhalla KN. Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies. J Clin Oncol 2005, 23:3971\u2013399.","journal-title":"J Clin Oncol"},{"key":"67_CR6","first-page":"4916","volume":"62","author":"R Furumai","year":"2002","unstructured":"Furumai R, Matsuyama A, Kobashi N, et al.: FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. Cancer Res 2002, 62:4916\u201321.","journal-title":"Cancer Res"},{"key":"67_CR7","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1182\/blood.V98.9.2865","volume":"98","author":"RL Piekarz","year":"2001","unstructured":"Piekarz RL, Robey R, Sandor V, et al.: Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report. Blood 2001, 98:2865\u20138.","journal-title":"Blood"},{"key":"67_CR8","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1182\/blood-2006-01-024703","volume":"109","author":"SP Perrine","year":"2007","unstructured":"Perrine SP, Hermine O, Small T, et al.: A phase 1\/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies. Blood 2007, 109:2571\u20138.","journal-title":"Blood"},{"key":"67_CR9","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1200\/JCO.2005.01.9679","volume":"24","author":"OA O\u2019Connor","year":"2006","unstructured":"O\u2019Connor OA, Heaney ML, Schwartz L, et al.: Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. J Clin Oncol 2006, 24:166\u201373.","journal-title":"J Clin Oncol"},{"key":"67_CR10","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1182\/blood-2006-06-025999","volume":"109","author":"M Duvic","year":"2007","unstructured":"Duvic M, Talpur R, Ni X, et al.: Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 2007, 109:31\u20139.","journal-title":"Blood"},{"key":"67_CR11","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1200\/JCO.2006.10.2434","volume":"25","author":"EA Olsen","year":"2007","unstructured":"Olsen EA, Kim YH, Kuzel TM, et al.: Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol 2007, 25:3109\u201315.","journal-title":"J Clin Oncol"},{"key":"67_CR12","doi-asserted-by":"crossref","first-page":"5410","DOI":"10.1200\/JCO.2008.21.6150","volume":"27","author":"RL Piekarz","year":"2009","unstructured":"Piekarz RL, Frye R, Turner M, et al.: Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol 2009, 27:5410\u20137.","journal-title":"J Clin Oncol"},{"key":"67_CR13","doi-asserted-by":"crossref","first-page":"4485","DOI":"10.1200\/JCO.2010.28.9066","volume":"28","author":"SJ Whittaker","year":"2010","unstructured":"\u2022\u2022 Whittaker SJ, Demierre MF, Kim EJ, et al.: Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J Clin Oncol 2010, 28:4485\u201391. This article describes the largest experience with romidepsin in CTCL and gives an excellent description of response criteria for CTCL studies.","journal-title":"J Clin Oncol"},{"key":"67_CR14","doi-asserted-by":"crossref","first-page":"1657a","DOI":"10.1182\/blood.V114.22.1657.1657","volume":"114","author":"R Piekarz","year":"2009","unstructured":"Piekarz R, Wright, J, Frye, R, . Final Results of a Phase 2 NCI Multicenter Study of Romidepsin in Patients with Relapsed Peripheral T-Cell Lymphoma (PTCL) [abstract]. Blood 2009, 114:1657a.","journal-title":"Blood"},{"key":"67_CR15","unstructured":"\u2022 Coiffier B, Horwitz S, Whittaker S: Romidepsin experience in 317 patients with T-cell lymphomas [abstract]. Proceedings of the European Hematology Association 2010:0572a. This abstract describes largest experience of a single drug in T-cell lymphomas and highlights important potential differences in toxicities between CTCL and PTCL."},{"key":"67_CR16","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.3324\/haematol.2009.008607","volume":"94","author":"D Ritchie","year":"2009","unstructured":"\u2022 Ritchie D, Piekarz R, Blombery P, et al.: Reactivation of DNA viruses in association with histone deacetylase inhibitor therapy: a case series report. Haematologica 2009, 94:1618\u201322. This article describes immunosuppressive properties of HDACi that may be greater than previously appreciated.","journal-title":"Haematologica"},{"key":"67_CR17","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1158\/1078-0432.CCR-05-2689","volume":"12","author":"MH Shah","year":"2006","unstructured":"Shah MH, Binkley P, Chan K, et al.: Cardiotoxicity of histone deacetylase inhibitor depsipeptide in patients with metastatic neuroendocrine tumors. Clin Cancer Res 2006, 12:3997\u20134003.","journal-title":"Clin Cancer Res"},{"key":"67_CR18","doi-asserted-by":"crossref","first-page":"3762","DOI":"10.1158\/1078-0432.CCR-05-2095","volume":"12","author":"RL Piekarz","year":"2006","unstructured":"Piekarz RL, Frye AR, Wright JJ, et al.: Cardiac studies in patients treated with depsipeptide, FK228, in a phase II trial for T-cell lymphoma. Clin Cancer Res 2006, 12:3762\u201373.","journal-title":"Clin Cancer Res"},{"key":"67_CR19","doi-asserted-by":"crossref","first-page":"7077","DOI":"10.1158\/1078-0432.CCR-09-1214","volume":"15","author":"PN Munster","year":"2009","unstructured":"Munster PN, Rubin EH, Van Belle S, et al.: A single supratherapeutic dose of vorinostat does not prolong the QTc interval in patients with advanced cancer. Clin Cancer Res 2009, 15:7077\u201384.","journal-title":"Clin Cancer Res"},{"key":"67_CR20","doi-asserted-by":"crossref","first-page":"920a","DOI":"10.1182\/blood.V114.22.920.920","volume":"114","author":"B Pohlman","year":"2009","unstructured":"Pohlman B, Advani R, Duvic M: Final results of a phase II trial of belinostat (PXD101) in patients with recurrent or refractory peripheral or cutaneous T-cell lymphoma [abstract]. Blood 2009, 114:920a.","journal-title":"Blood"},{"key":"67_CR21","doi-asserted-by":"crossref","first-page":"3500a","DOI":"10.1200\/jco.2007.25.18_suppl.3500","volume":"25","author":"M Prince","year":"2007","unstructured":"Prince M, George D, Patnaik A: Phase I study of oral LBH589, a novel deacetylase (DAC) inhibitor in advanced solid tumors and non-Hodgkin\u2019s lymphoma [abstract]. J Clin Oncol 2007, 25:3500a.","journal-title":"J Clin Oncol"},{"key":"67_CR22","first-page":"112","volume":"2008","author":"M Duvic","year":"1005","unstructured":"Duvic M, Becker JC, Dalle S: Phase II trial of oral panobinostat (LBH589) in patients with refractory cutaneous T-cell lymphoma (CTCL) [abstract]. Blood 2008, 112:1005a.","journal-title":"Blood"},{"key":"67_CR23","doi-asserted-by":"crossref","first-page":"8572","DOI":"10.1200\/jco.2009.27.15_suppl.8572","volume":"27","author":"R Dummer","year":"2009","unstructured":"Dummer R, Hymes K, Sterry W. Vorinostat in combination with bexarotene in advanced cutaneous T-cell lymphoma: a phase I study [abstract]. J Clin Oncol 2009, 27:8572.","journal-title":"J Clin Oncol"},{"key":"67_CR24","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1182\/blood-2008-04-149658","volume":"113","author":"J Chen","year":"2009","unstructured":"Chen J, Zhang M, Ju W, Waldmann TA. Effective treatment of a murine model of adult T-cell leukemia using depsipeptide and its combination with unmodified daclizumab directed toward CD25. Blood 2009, 113:1287\u201393.","journal-title":"Blood"},{"key":"67_CR25","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1111\/j.1600-0609.2009.01239.x","volume":"82","author":"U Heider","year":"2009","unstructured":"Heider U, Rademacher J, Lamottke B, et al.: Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in cutaneous T cell lymphoma. Eur J Haematol 2009, 82:440\u20139.","journal-title":"Eur J Haematol"},{"key":"67_CR26","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1038\/leu.2009.41","volume":"23","author":"QL Zhang","year":"2009","unstructured":"Zhang QL, Wang L, Zhang YW, et al.: The proteasome inhibitor bortezomib interacts synergistically with the histone deacetylase inhibitor suberoylanilide hydroxamic acid to induce T-leukemia\/lymphoma cells apoptosis. Leukemia 2009, 23:1507\u201314.","journal-title":"Leukemia"},{"key":"67_CR27","doi-asserted-by":"crossref","first-page":"5250","DOI":"10.1158\/1078-0432.CCR-08-2850","volume":"15","author":"A Badros","year":"2009","unstructured":"Badros A, Burger AM, Philip S, et al.: Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma. Clin Cancer Res 2009, 15:5250\u20137.","journal-title":"Clin Cancer Res"},{"key":"67_CR28","doi-asserted-by":"crossref","first-page":"3698","DOI":"10.1182\/blood.V112.11.3698.3698","volume":"112","author":"SJ Harrison","year":"2008","unstructured":"Harrison SJ, Quack H, Yuen K. High response rates with the combination of bortezomib, dexamethasone and the pan-histone deacetylase inhibitor romidepsin in patients with relapsed or refractory multiple myeloma in a phase I\/II clinical trial [abstract]. Blood 2008, 112:3698.","journal-title":"Blood"},{"key":"67_CR29","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1002\/cncr.25377","volume":"116","author":"G Dueck","year":"2010","unstructured":"Dueck G, Chua N, Prasad A, et al.: Interim report of a phase 2 clinical trial of lenalidomide for T-cell non-Hodgkin lymphoma. Cancer 2010, 116:4541\u20138.","journal-title":"Cancer"},{"key":"67_CR30","doi-asserted-by":"crossref","unstructured":"Siegel DS, Weber, D. M, Mitsiades,C. S. Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed\/refractory multiple myeloma: A phase I study [abstract]. J Clin Oncol 2009, 27:abstract 8586.","DOI":"10.1200\/jco.2009.27.15_suppl.8586"}],"container-title":["Current Hematologic Malignancy Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-010-0067-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11899-010-0067-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-010-0067-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,13]],"date-time":"2021-11-13T14:46:06Z","timestamp":1636814766000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11899-010-0067-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,11,16]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,3]]}},"alternative-id":["67"],"URL":"https:\/\/doi.org\/10.1007\/s11899-010-0067-5","relation":{},"ISSN":["1558-8211","1558-822X"],"issn-type":[{"value":"1558-8211","type":"print"},{"value":"1558-822X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,11,16]]}}}